Kamada (Israel) Top Management
| KMDA Stock | ILA 2,771 95.00 3.31% |
Kamada employs about 355 people. The company is managed by 30 executives with a total tenure of roughly 265 years, averaging almost 8.0 years of service per executive, having 11.83 employees per reported executive. Analysis of Kamada's management performance can provide insight into the company performance.
| Amir London CEO Chief Executive Officer |
| David Tsur Chairman Co-Founder and Deputy Executive Chairman |
Kamada |
Kamada Management Team Effectiveness
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.Kamada maintains a total of 44.8 Million outstanding shares. 30% of Kamada outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Kamada in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Kamada, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Kamada Workforce Comparison
Kamada is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 802. Kamada totals roughly 355 in number of employees claiming about 44% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.01) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.01. Kamada Benchmark Summation
The output start index for this execution was one with a total number of output elements of sixty. The Lowest value over a specified period line plots minimum value of Kamada price series.
Kamada Notable Stakeholders
A Kamada stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kamada often face trade-offs trying to please all of them. Kamada's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kamada's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Amir London | Chief Executive Officer | Profile | |
| David Tsur | Co-Founder and Deputy Executive Chairman | Profile | |
| Leon Recanati | Chairman of the Board | Profile | |
| Pnina Strauss | Vice President - Inhalation programs & IP | Profile | |
| Barak Bashari | Vice President - Operations | Profile | |
| Eran Schenker | Vice President - Medical Director | Profile | |
| Michal Stein | Vice President and Medical Director for Immunology | Profile | |
| Shani Dotan | Vice President of Human Resources | Profile | |
| Yael Brenner | Vice President - Quality | Profile | |
| Ruth Wolfson | Senior Vice President - Scientific Affairs | Profile | |
| Naveh Tov | Vice President-Clinical Development and Medical Director for Pulmonary Diseases | Profile | |
| Orit Pinchuk | Vice President - Regulatory Affairs and Quality R&D | Profile | |
| Michal Ayalon | Vice President - Research & Development | Profile | |
| Eitan Kyiet | Vice President - Business Development | Profile | |
| Chaime Orlev | Chief Financial Officer | Profile | |
| Itzhak Krinsky | Director | Profile | |
| Tuvia Shoham | Independent Director | Profile | |
| Abraham Havron | Independent Director | Profile | |
| Shmuel Rubinstein | Director | Profile | |
| Michael Berelowitz | Director | Profile | |
| Jonathan Hahn | Director | Profile | |
| Gwen Melincoff | Director | Profile | |
| Estery GilozRan | Independent Director | Profile | |
| Lilach Topilsky | Chairman of the Board | Profile | |
| Ari Shamiss | Director | Profile | |
| Eran Nir | Chief Officer | Profile | |
| Hanni Neheman | VP Sales | Profile | |
| Ariella Raban | VP HR | Profile | |
| Jon Knight | VP Operations | Profile | |
| Yifat Esq | Gen Legal | Profile |
About Kamada Management Performance
The success or failure of an entity such as Kamada often depends on how effective the management is. Kamada management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kamada management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kamada management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 408 people.
Please note, the presentation of Kamada's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kamada's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kamada's management manipulating its earnings.
Kamada Workforce Analysis
Traditionally, organizations such as Kamada use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kamada within its industry.Kamada Manpower Efficiency
Return on Kamada Manpower
| Revenue Per Employee | 291.9K | |
| Revenue Per Executive | 3.5M | |
| Net Loss Per Employee | 6.3K | |
| Net Loss Per Executive | 74.3K | |
| Working Capital Per Employee | 163.4K | |
| Working Capital Per Executive | 1.9M |
Complementary Tools for Kamada Stock analysis
When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |